



Contact: Jim Hamby
Ash Stevens Inc.
jhamby@ashstevens.com
734-282-3370 x 1144

Ken Li
Chempetitive Group
kli@chempetitive.com
312-997-2436 x 111

**ASH STEVENS INC. CEO TO CHAIR SESSION ON CANCER DRUG
DEVELOPMENT AT AMERICAN ASSOCIATION FOR CANCER RESEARCH
ANNUAL MEETING**

Detroit–April 8, 2009–Ash Stevens Inc.™ (ASI) President and CEO Dr. Stephen Munk will chair an educational session for the Chemistry in Cancer Research Working Group (CICR) at the American Association for Cancer Research (AACR) annual meeting on Saturday, April 18, 2009 at the Colorado Convention Center in Denver, Colorado.

Dr. Munk’s session will highlight the unique developmental challenges of safely manufacturing highly potent active pharmaceutical ingredients (APIs) used in cancer drugs. Speakers from a broad range of research institutions involved with early stage compounds and approved drugs will participate including Southern Research Institute, Medivation, Inc., and Millennium Pharmaceuticals, Inc.. The title of the session is “From Chemistry to the Clinic: Pathways for Drug Discovery and Development Part 4: Chemical Development – Translating a Potent Agent into a Registered Product”.

About Ash Stevens, Inc.

Headquartered in Detroit, Ash Stevens, Inc. (ASI) was founded in 1962 to service the chemical research needs of the Federal Government. ASI has extensive experience in the development and scale-up of commercial cancer APIs and shares a longstanding and successful relationship with the National Cancer Institute. ASI has a total of 11 FDA approved drug substances in its portfolio. The company has more than 60 employees and holds patents in both medicinal and process chemistry. For more information, visit www.ashstevens.com.

###